Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Stéphane De Wit is active.

Publication


Featured researches published by Stéphane De Wit.


Epidemiology and Infection | 2017

Isolation unit for multidrug-resistant tuberculosis patients in a low endemic country, a step towards the World Health Organization End TB Strategy

Marie-Christine Payen; Jean-Paul Van Vooren; Olivier Vandenberg; Nathan Clumeck; Stéphane De Wit

Tuberculosis (TB) remains a threat to public health and is the second cause of death due to a single infectious agent after HIV/AIDS. The worldwide distribution of TB is heterogeneous. The incidence is decreasing in most high-income regions, but the situation remains worrying in many parts of the world. The emergence of Mycobacterium tuberculosis strains resistant to key agents used in treatment (rifampin and isoniazid) contributes to TB transmission around the world. To achieve TB elimination, both high and low endemic countries must upscale their efforts to decrease disease transmission and improve cure rates. Management of drug-resistant TB is of particular importance. In this paper, we discuss the different models of care of multidrug-resistant TB (MDR-TB), the ethical considerations and the specific constraints present in high income countries. The management model chosen by the Belgian TB specialists in accordance with public health authorities as well as building of a specific MDR/XDR-TB isolation unit are also discussed.


Archive | 1998

Combined quadruple therapy with Ritonavir-Saquinavir+ nucleosides in patients who failed in triple therapy with Ritonavir, Saquinavir or Indinavir

P. Cassano; Philippe Hermans; Bernadette Sommereijns; Stéphane De Wit; Kabamba Kabeya; Elizabeth O'Doherty; Nathan Clumeck


Archive | 2002

Virological response to salvage therapy at 6 month in patients with B or non-B subtypes.

Philippe Hermans; Jean-Claude Schmit; Kabamba Kabeya; Elizabeth O'Doherty; Stéphane De Wit; Bernadette Sommereijns; Nathan Clumeck


Archive | 1999

Virological and immunological effects of Hydroxyurea salvage therapy in HIV infected patients

Philippe Hermans; Stéphane De Wit; Kabamba Kabeya; Bernadette Sommereijns; Nathan Clumeck


Archive | 1999

Cutaneous adverse events with abacavir and NNRTI combination: benefit of a delayed introduction of NNRTI

Kabamba Kabeya; Stéphane De Wit; Philippe Hermans; Elizabeth O'Doherty; Nathan Clumeck


Archive | 1998

MIRO: a randomized trial of maintenance therapy with or whitout protease inhibitors after 4 months of triple or quadruple induction therapy

Nathan Clumeck; Nankavu-Jeanne Mundere; Kabamba Kabeya; Deborah Konopnicki; Bernadette Sommereijns; Elizabeth O'Doherty; Suzanne Sprecher; Philippe Hermans; Claire-Michèle Farber; Jean Claude Legrand; Jean-Paul Van Vooren; Pascal Pierre; Stéphane De Wit


Archive | 1998

141W94-AZT-3TC association:: a novel protease inhibitor added to long-standing AZT-3TC of combined with new reverse transcriptase inhibitors

P. Cassano; Stéphane De Wit; Philippe Hermans; Kabamba Kabeya; Marcel Gérard; Bernadette Sommereijns; Elizabeth O'Doherty; Nathan Clumeck


Archive | 1998

Genotypic and phenotypic sensitivity of viral isolates, in patients failing to AZT-3TC-141W94

P. Cassano; Philippe Hermans; Stéphane De Wit; Kabamba Kabeya; Elizabeth O'Doherty; Margaret Tisdale; Jane Yeo; Nathan Clumeck


Archive | 1998

Viral and immune response to Nelfinavir-Saquinavir or Ritonavir-Saquinavir, in HIV+ patients heavily pretreated with protease inhibitors

P. Cassano; Stéphane De Wit; Marcel Gérard; Philippe Hermans; Bernadette Sommereijns; Kabamba Kabeya; Frédérique De Cock; Nathan Clumeck


Archive | 1998

Picasso: a randomized comparative outcome trial of indinavir and ritonavir in protease inhibitors naiv HIV patients with CD4 below 100 cells/µl

Kabamba Kabeya; Stéphane De Wit; Bernadette Sommereijns; P. Cassano; Bernard Vandercam; B. Colebunders; Nathan Clumeck

Collaboration


Dive into the Stéphane De Wit's collaboration.

Top Co-Authors

Avatar

Nathan Clumeck

Université libre de Bruxelles

View shared research outputs
Top Co-Authors

Avatar

Philippe Hermans

Rega Institute for Medical Research

View shared research outputs
Top Co-Authors

Avatar

B. Colebunders

Institute of Tropical Medicine Antwerp

View shared research outputs
Top Co-Authors

Avatar

Bernard Vandercam

Cliniques Universitaires Saint-Luc

View shared research outputs
Top Co-Authors

Avatar

Jean-Paul Van Vooren

Université libre de Bruxelles

View shared research outputs
Top Co-Authors

Avatar

Claire-Michèle Farber

Université libre de Bruxelles

View shared research outputs
Top Co-Authors

Avatar

Deborah Konopnicki

Université libre de Bruxelles

View shared research outputs
Top Co-Authors

Avatar

Jean-Claude Schmit

Katholieke Universiteit Leuven

View shared research outputs
Top Co-Authors

Avatar

Kabamba Kabeya

Université libre de Bruxelles

View shared research outputs
Top Co-Authors

Avatar

Marie-Christine Payen

Université libre de Bruxelles

View shared research outputs
Researchain Logo
Decentralizing Knowledge